Cynvenio's LiquidBiopsy rare cell isolation platform will be featured at Molecular Med Tri-Con 2017 - booth 128.
For NGS applications, the LiquidBiopsy platform delivers an end-to-end, blood-to-sequence workflow that runs faster and more precisely on less than 10ng of DNA input material than approaches from competing vendors.
For molecular characterization via FISH or IHC the LiquidBiopsy platform delivers target cells that can be stained, enumerated and microscopically characterized using standard fluorescent or immunohistochemical protocols. Alternatively, the product of the LiquidBiopsy platform is compatible with FISH and single cell applications.
The LiquidBiopsy system is widely deployed in support of research applications in oncology and non-invasive prenatal testing.